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Reprogramming of cellular metabolism plays a
central role in fueling malignant transformation, and
AMPK and the PGC-1a/ERRa axis are key regulators
of this process. The intersection of gene-expression
and binding-event datasets for breast cancer cells
shows that activation of AMPK significantly in-
creases the expression of PGC-1a/ERRa and pro-
motes the binding of ERRa to its cognate sites. Unex-
pectedly, the data also reveal that ERRa, in concert
with PGC-1a, negatively regulates the expression
of several one-carbon metabolism genes, resulting
in substantial perturbations in purine biosynthesis.
This PGC-1a/ERRa-mediated repression of one-car-
bon metabolism promotes the sensitivity of breast
cancer cells and tumors to the anti-folate drug meth-
otrexate. These data implicate the PGC-1a/ERRa
axis as a core regulatory node of folate cycle meta-
bolism and further suggest that activators of AMPK
could be used to modulate this pathway in cancer.INTRODUCTION
The orphan nuclear receptor known as estrogen-related recep-
tor a (ERRa, NR3B1) and the peroxisome proliferator-activated
receptor g co-activator 1a (PGC-1a) act together as a transcrip-
tional regulatory node important for the expression of metabolic
genes (Deblois et al., 2013; Gigue`re, 2008; Mootha et al., 2004;
Villena and Kralli, 2008). Indeed, the PGC-1a/ERRa axis is now
well established as a central regulator of energy metabolism
that induces the global expression of genes involved in mito-
chondrial biogenesis and functions (Eichner and Gigue`re,
2011; Gigue`re, 2008; Handschin and Spiegelman, 2006). Specif-
ically, gene expression and genome-wide binding analyses920 Cell Reports 14, 920–931, February 2, 2016 ª2016 The Authorsdemonstrated that PGC-1a and ERRa share a functional rela-
tionship in controlling the expression of vast metabolic gene net-
works in numerous tissues (Chang et al., 2011; Deblois et al.,
2010; Laganie`re et al., 2004; Schreiber et al., 2004; Wende
et al., 2005). ERRa binds to the promoters of all genes encoding
enzymes of glycolysis andmany nuclear-encodedmitochondrial
genes involved in energy metabolism (Charest-Marcotte et al.,
2010; Dufour et al., 2007; Eichner and Gigue`re, 2011). Moreover,
PGC-1a and ERRa exploit auto-regulatory feedforward loops
to promote the expression of metabolic genes andmitochondrial
activity (Handschin et al., 2003; Laganie`re et al., 2004; Mootha
et al., 2004; Schreiber et al., 2004).
The expression and activity of ERRa and PGC-1a are highly
adaptable and can respond to various physiological and patho-
logical cues. In support of this point, PGC-1a is a key effector of
the energy-sensing signaling cascade orchestrated by AMP-
activated protein kinase (AMPK) (Ja¨ger et al., 2007). AMPK oc-
cupies a central position in the reprogramming of cells to adapt
to metabolic stress by promoting catabolism and inhibiting
anabolism in order to restore the pool of cellular ATP (Hardie
et al., 2012). Specifically, AMPK promotes catabolic reactions,
such as lipid oxidation and cellular respiration, and inhibits
anabolic processes, such as lipid and protein synthesis (Hardie
et al., 2012). AMPK activation induces the expression of
PGC-1a, and the AMPK-mediated increase in mitochondrial
respiration has been shown to be dependent on PGC-1a in
muscle cells (Ja¨ger et al., 2007). In addition, AMPK phosphory-
lates PGC-1a, which potentiates its activity (Ja¨ger et al., 2007).
Clearly, PGC-1a is a significant downstream effector of AMPK-
dependent metabolic effects, but which specific pathways are
regulated by the AMPK/PGC-1a/ERRa partnership are yet to
be identified.
The PGC-1a/ERRa axis is a central regulator of metabolism in
cancer, notably breast cancer (Deblois and Gigue`re, 2013; De-
blois et al., 2013). The expression of PGC-1a is reduced in breast
tumors compared with normal tissues (Deblois et al., 2013).
However, within the various breast cancer subtypes, the levels
of PGC-1a, along with that of ERRa, are highest in HER2+ and
triple-negative breast tumors, the two breast cancer subtypes
associated with the poorest prognosis (Ariazi et al., 2002; De-
blois et al., 2009; McGuirk et al., 2013). Functional studies
have shown that PGC-1a promotes the growth of HER2+ tumors
by regulating intra-tumoral nutrient availability (Klimcakova et al.,
2012). ERRa also promotes the growth of HER2+ breast tumors
by promoting the expression of the HER2 amplicon (Deblois
et al., 2010), and the ERRa signaling axis is downstream of
HER2 (Ariazi et al., 2007; Barry and Gigue`re, 2005; Chang
et al., 2011). In addition, a recent study has shown that the
PGC-1a/ERRa axis is a positive regulator of glutamine meta-
bolism in HER2+ breast tumors and that elevated expression
of glutamine enzymes is associated with poor clinical outcome
in breast cancer patients (McGuirk et al., 2013). Overall,
increasing experimental evidence supports a role for the PGC-
1a/ERRa axis in fueling breast tumor growth.
Histological analyses of phospho-AMPK in breast tumors
showed that AMPK signaling is reduced in breast cancer
compared with normal tissues (Hadad et al., 2008). Furthermore,
reduced AMPK signaling in breast tumors is associated with
poor clinical outcome (Hadad et al., 2008). However, functional
studies have shown both pro- and anti-growth effects of
AMPK in breast cancer (Fox et al., 2013; Laderoute et al.,
2014). The impact of AMPK on breast cancer growth is associ-
ated with metabolic changes (Laderoute et al., 2014), and meta-
bolic effectors, such as PGC-1a, likely play a central role inmedi-
ating the AMPK-dependent metabolic effects. Indeed, recent
studies revealed that the AMPK/PGC-1a signaling cascade in
various cancers causes metabolic perturbations and promotes
growth (Huang et al., 2014; Tennakoon et al., 2014; Yan et al.,
2014). Most of the metabolic perturbations associated with the
AMPK/PGC-1a signaling cascade relate to mitochondrial meta-
bolism. However, little is known regarding the global impact of
the AMPK/PGC-1a axis on cancer metabolism.
In this study, we uncovered a role for the AMPK/PGC-1a/
ERRa signaling cascade in repressing one-carbon metabolism
by using a combination of functional genomics and metabolo-
mics approaches. One-carbon metabolism plays a central role
in dividing cells by participating in the synthesis of nucleotides,
and hyperactivation of this metabolic pathway is linked to onco-
genesis (Locasale, 2013). The clinical relevance of our data is
highlighted by the fact that the AMPK/PGC-1a/ERRa-dependent
regulation of one-carbon metabolism promotes sensitivity to
anti-folate therapy in the context of breast cancer.
RESULTS
AMPK Activation Promotes PGC-1a/ERRa-Dependent
Metabolic Reprogramming
To study the interplay between the metabolic regulators AMPK,
PGC-1a, and ERRa in breast cancer, we used two human cell
lines of HER2+ breast cancer, namely, BT474 and SKBR3. Both
of these cell lines display high ERRa activity, overexpress
HER2, and are dependent on aerobic glycolysis (Chang et al.,
2011; Deblois et al., 2009). To activate AMPK, we used three
different compounds, namely, AICAR (5-aminoimidazole-4-
carboxamide 1-b-ribofuranoside) (Figure 1A; Figures S1A andCS1B), A769662 (Figure S1C), and metformin (Figure S1D) (Cool
et al., 2006; Corton et al., 1995). AMPK activation increased
the expression of PPARGC1A (PGC-1a) and ESRRA (ERRa),
but not that ofPPARCG1B (PGC-1b) orESRRG (ERRg), suggest-
ing that AMPK specifically modulates the PGC-1a/ERRa axis
(Figure 1B; Figures S1A, S1E, and S1F). This is in line with pub-
lished results in a non-transformed cell line showing that AMPK
phosphorylates PGC-1a increasing its level and activity (Ja¨ger
et al., 2007) and that PGC-1a promotes ERRa expression result-
ing in a positive feedback loop in which ERRa stimulates its
own expression (Laganie`re et al., 2004; Mootha et al., 2004).
AMPK activation stimulated the expression of known targets of
the PGC-1a/ERRa axis, such as genes encoding enzymes of
the citric acid cycle (CS, FH,MDH2) and a component of the elec-
tron transport chain (NDUFB5) (Figure 1B; Figure S1E). To vali-
date the biological significance of these changes in expression
of metabolic genes, we assessed the bioenergetics status of
these two cell lines by measuring their glycolytic and mitochon-
drial respiration capacities. AMPK activation decreased aerobic
glycolysis as illustrated by reduced lactate production (Fig-
ure S1G), increased cellular respiration (Figure 1C; Figure S1H),
and altered the balance between coupled and uncoupled respi-
ration (Figure 1D; Figure S1I). This pattern of mitochondrial
respiration is typical of cells with elevated PGC-1a expression
(St-Pierre et al., 2003). To test whether the metabolic changes
seen upon AMPK activation were dependent on the PGC-1a/
ERRa axis, we used siRNA targeting PGC-1a or ERRa. Knock-
down of either PGC-1a or ERRa nearly completely abolished
the AMPK-mediated increase in ERRa expression and in respi-
ration (Figures 1E and 1F). Collectively, these data show that
AMPK activation in breast cancer cells increases the activity
of the PGC-1a/ERRa axis and that this transcriptional node
plays a central role in promoting AMPK-dependent increase in
cellular respiration.
AMPK Activation Induces ERRa Binding Events on a
Genome-wide Scale
To gain a global understanding of the PGC-1a/ERRa-dependent
transcriptional events downstream of AMPK, we first performed
chromatin immunoprecipitation coupled with deep sequencing
(ChIP-seq) experiments for ERRa following AICAR treatment in
BT474 cells (Figure 2; Figure S2). Under basal conditions,
ERRa was bound to more than 22,000 genomic regions and
the binding was enriched near genes involved in metabolic path-
ways, most notably, mitochondrial functions (Figures S2A–S2D).
AMPK activation increased the total number of binding sites for
ERRa by more than 50% (Figure 2A). Heatmaps of ChIP-seq
data showed that the sites strongly bound by ERRa in basal
conditions tended to stay bound during AMPK activation (Fig-
ure 2B), including the ERRa binding site localized at its own pro-
moter (Figure S2C). It is important to note that significant binding
events for ERRa following AICAR treatment also seemed to be
present under basal conditions, although below the threshold
for peak calling. These data thus indicate that AMPK activation
does not significantly change the global ERRa binding site
distribution, but rather, it modulates ERRa binding to sites dis-
playing lower affinity for ERRa in the absence of a stimulus (Fig-
ure 2B). Validation of ChIP-seq data using standard ChIP-qPCRell Reports 14, 920–931, February 2, 2016 ª2016 The Authors 921
Figure 1. AMPK Increases Mitochondrial
Metabolism in Human Breast Cancer Cells
in a PGC-1a/ERRa-Dependent Manner
(A) Immunoblots of phosphorylated-ACC (S79),
total ACC, phosphorylated-AMPKa (T172), and
total AMPKa in BT474 cells upon 0.5 mM AICAR or
vehicle treatment for 24 hr or 96 hr.
(B) Expression of PPARGC1 and ESRR family
members and their metabolic target genes in
BT474 cells in the presence of 0.5 mM AICAR for
96 hr, normalized to that of BT474 cells treatedwith
vehicle (n = 5) (dashed line).
(C) Total (T), uncoupled (U), and coupled (C)
respiration of BT474 cells treated with 0.5 mM
AICAR for 96 hr, normalized to that of BT474 cells
treated with vehicle (n = 6) (dashed line).
(D) Percentage of mitochondrial respiration that is
coupled and uncoupled, calculated from (C) (n = 6).
(E) Total, uncoupled, and coupled respiration of
BT474 cells transfected with siC, siPGC-1a, or si-
ERRa, and treated with 0.5 mM AICAR for 96 hr,
normalized to that of transfected BT474 cells
treated with vehicle (n = 7) (dashed line).
(F) Expression of PPARGC1A and ESRRA in BT474
cells transfected with siC, siPGC-1a, or siERRa
and treated with 0.5 mM AICAR for 96 hr, normal-
ized to that of transfected BT474 cells treated with
vehicle (n = 7) (dashed line).
All data are presented as means + SEM, *p < 0.05,
Student’s t test.
See also Figure S1.showed loci to which ERRa binding is either unregulated or regu-
lated in a positive or negative manner in the presence of AICAR
(Figure 2C). Pathway and motif enrichment analyses comprising
all bound genes identified by ChIP-seq did not reveal major
differences between basal or AMPK-activated conditions. In
fact, themost enriched pathways in both conditions were related
to cellular metabolism, notably, mitochondrial functions (Fig-
ure S2D). Also, the ERR response element (ERRE) motif was
the most significantly enriched motif in both conditions, with no
major change observed in other significantly co-enriched motifs
such as FOXA1, AP-1, and AP-2 (Figure S2E).
These results were confirmed in SKBR3 cells (Figure S2F). In
addition, we validated that AMPK activation induces ERRa bind-
ing near the transcriptional start site of known ERRa metabolic
targets in mouse embryonic fibroblasts (MEFs) (Figure S2G).
Importantly, this AICAR-mediated induction of ERRa binding
was impaired in MEFs null for PRKAA1 and PRKAA2, encoding
the two a subunits of AMPK (Figure S2G), illustrating that the
induction of ERRa binding upon AICAR treatment is dependent
on AMPK. Together, these results show that ERRa binding is
increased following AMPK activation in human and mouse cells.
The PGC-1a/ERRa Axis Negatively Controls the
Expression of Folate Cycle Genes
To reveal the main pathways targeted by increased ERRa
binding following AMPK activation, we first looked at the inter-922 Cell Reports 14, 920–931, February 2, 2016 ª2016 The Authorsconnection between microarray and ChIP-seq datasets. Specif-
ically, we looked for genes that displayed changes in expression
and that were associated with an ERRa binding event following
AMPK activation (Figure 3A). The most significantly enriched
pathways connected with these 413 genes were linked to folate
metabolism such as histidine degradation, folate transformation,
and tetrahydrofolate salvage (Figures 3B and 3C). These results
were validated using qPCR showing that the expression of
several folate cycle genes was reduced following AMPK activa-
tion (Figure 3D, yellow bars). The observed downregulation in the
expression of folate cycle genes was ERRa-dependent because
ERRa knockdown attenuated the reduction in folate cycle gene
expression upon AMPK activation (Figure 3D, compare the
orange and red bars).
These results were validated with a separate AMPK activator,
A769662 (FigureS3). Furthermore, theAMPKactivatormetformin
also led to elevated levels of PGC-1a and ERRa along with
repression of the folate cycle geneMTHFD1 (Figure S1F). ChIP-
qPCR validation experiments confirmed that ERRa binding was
increased at several folate cycle gene promoters upon AMPK
activation (Figure 3E). In addition, the data revealed that ERRa
knockdown, in the absence of AMPK activation in BT474 cells,
significantly increased the expression of several folate cycle
genes (Figures 3D, blue bars, and 3F) indicating that under basal
conditions ERRa negatively regulates the expression of folate cy-
cle genes. PGC-1a knockdown also significantly increased the
Figure 2. AMPKActivation InducesGenomic ERRaBinding in Breast
Cancer Cells
(A) Venn diagrams representing number of ERRa-bound segments obtained
by ChIP-seq in BT474 cells upon 90 min stimulation with 0.5mM AICAR or
vehicle.
(B) Heatmaps showing signal intensities of ERRa binding by ChIP-seq in
BT474 cells upon 0.5 mM AICAR or vehicle treatment and clustered according
to overlapping peaks. The window represents a region covering ± 2.5 kb
around the center of the binding event.
(C) Standard ChIP-qPCR validation of ERRa binding in BT474 cells at several
target genes upon treatment with 0.5 mM AICAR or vehicle for 90 min. Results
are presented as the average of at least three independent experiments.
See also Figure S2.level of MTHFD1L in these cells (Figure 3F), whereas overexpres-
sion of PGC-1a in murine cells expressing activated ERBB2
(NT2196 cells) led to a sharp decrease in the level of MTHFD1L
(Figure 3G). Altogether, these results reveal that the PGC-1a/
ERRa axis negatively controls the expression of several folate
cycle genes under basal conditions and in response to AMPK
activation in HER2+ breast cancer cells.
The PGC1a/ERRa Axis Represses Folate Metabolism
and Purine Biosynthesis
Folate intermediates play a central role in one-carbon meta-
bolism reactions. They are used as messengers of one-carbon
units for the de novo production of purines and the formation
of thymidylate, both of which are important for nucleotide syn-
thesis and cell proliferation (Locasale, 2013). Folate intermedi-
ates also play a central role in the replenishment of S-adeno-
syl-methionine (SAM) for methylation reactions (Locasale,
2013). Given the modest, but concerted, repression of the
expression of several folate cycle genes by the PGC-1a/ERRaCaxis, we evaluated its impact on one-carbon metabolism. To
do so, we first assessed the impact of the PGC-1a/ERRa axis
on nucleotide synthesis by quantifying DNA synthesis and cell
proliferation. Knockdown of either PGC-1a or ERRa increased
DNA synthesis and cell proliferation in BT474 cells (Figures
4A and 4B). Conversely, AMPK activation, which activates the
PGC-1a/ERRa axis (Figure 1), decreased DNA synthesis
(Figure 4C) and cell proliferation (Figure 4D; Figure S4A). Taken
together, these results indicate that the PGC-1a/ERRa axis
acts as a repressor of nucleotide synthesis and cell proliferation.
In order to substantiate these results, we quantified the
impact of the PGC-1a/ERRa axis on the expression of key purine
biosynthesis enzymes, namely, phosphoribosyl pyrophosphate
amidotransferase (PPAT), phosphoribosylglycinamide for-
myltransferase, phosphoribosylglycinamide synthetase, phos-
phoribosylaminoimidazole synthetase (GART), and 5-aminoimi-
dazole-4-carboxamide ribonucleotide formyltransferase/IMP
cyclohydrolase (ATIC). PPAT is the enzyme catalyzing the rate-
limiting step in de novo purine synthesis, and GART and ATIC
receive the one-carbon unit from the folate cycle. Knockdown
of either PGC-1a or ERRa in BT474 cells increased the expres-
sion of PPAT, GART, and ATIC (Figure 4E). ChIP-qPCR analysis
confirmed binding of ERRa to the promoter of PPAT,GART, and
ATIC and positive regulation of ERRa binding at these loci
following AMPK activation (Figure 4F). AMPK activation in
BT474 cells, which activates the PGC-1a/ERRa axis, decreased
the expression of PPAT, GART, and ATIC, but it only reached
statistical significance for GART. Importantly, the AMPK-medi-
ated repression of all three genes was reversed upon treatment
with siERRa (Figure 4G, compare the orange and red bars). Addi-
tionally, both ATIC and GART were increased at the protein level
upon ERRa repression (Figure 4H). On the other hand, PGC-1a
overexpression in NT2196 cells, which was paralleled by
increased ERRa expression (Figure S4B), decreased the expres-
sion of PPAT, GART, and ATIC (Figure 4I). Together, these data
demonstrate that the PGC-1a/ERRa axis acts as a repressor of
the expression of purine biosynthesis enzymes.
To directly assess whether these changes in the expression of
purine biosynthesis genes had an impact on purine biosynthesis,
we established a stable isotope tracer analysis methodology
to follow the incorporation of labeled serine (13C3-
15N-serine)
into AMP, ATP, and S-adenosyl methionine (SAM), which is a
component of the methionine cycle that is directly linked to
the folate cycle (Figure 4J). Knockdown of ERRa in BT474
cells, which was paralleled by reduced PGC-1a expression (Fig-
ure S4C), increased the fraction of labeled AMP (m+1–5), ATP
(m+1–5) and SAM (m+1–5) (Figures 4K–4M). Conversely, overex-
pression of PGC-1a decreased the fraction of labeled ATP (m+1–
5) (Figure 4N). This was accompanied by decreased formate
levels, a one-carbon unit that links folate metabolism to purine
biosynthesis (Figure 4O). Overall, these results demonstrate
that the PGC-1a/ERRa axis represses folate metabolism and
purine biosynthesis.
The PGC-1a/ERRa Axis Sensitizes Cells and Tumors to
Methotrexate
Given that the PGC-1a/ERRa axis is a negative regulator of folate
metabolism, we assessed whether this regulatory complexell Reports 14, 920–931, February 2, 2016 ª2016 The Authors 923
Figure 3. The PGC-1a/ERRa Axis Re-
presses Folate Metabolism Gene Expres-
sion
(A) Venn diagrams representing the overlap be-
tween ERRa peaks unique to BT474 cells treated
with 0.5 mM AICAR (ChIP-seq) and the genes
whose expression is significantly altered upon
0.5mMAICAR treatment (microarray). The number
of genes in each group is shown.
(B) Pathways enriched in the overlap of the
Venn diagrams in (A). Values greater than 1.3
(red dashed line) indicate statistical significance
(p < 0.05).
(C) Schematic representation of the folate meta-
bolic pathways in the cytoplasm andmitochondria.
Upon AICAR treatment, the expression of enzymes
boxed in pink are downregulated and the
genes encoding the enzymes marked with a
yellow star are associated with an ERRa binding
event. DHF: dihydrofolate; THF: tetrahydrofolate;
10-FTHF: 10-formylTHF; 5,10-MTHF: 5,10-
methyleneTHF; 5,10-mTHF: 5,10-methenylTHF; 5-
MTHF: 5-methylTHF.
(D) Relative expression of folate metabolism genes
in BT474 cells transfected with siC or siERRa, and
treated with 0.5 mM AICAR or vehicle for 24 hr,
normalized to that of siC cells treated with vehicle
(n = 3). Data are shown as means and SEM, # p <
0.05; ## p < 0.01; ### p < 0.001 indicate that
AICAR induces a significant change in expression
compared with vehicle treatment; *p < 0.05; **p <
0.01; ***p < 0.001 indicate that siERRa induces a
significant change compared with siC (Student’s t
test). Immunoblots of phosphorylated-ACC (S79),
total ACC, and ERRa in BT474 cells transfected
with siC or siERRa and treated with 0.5 mM AICAR
or vehicle for 24 hr are shown in the inset. Tubulin
represents the loading control.
(E) StandardChIP-qPCRvalidation of ERRabinding
to several MTHFD family genes in BT474 cells
treated with AICAR or vehicle for 90 min (n = 3).
(F) Immunoblots of MTHFD1L in BT474
cells transfected with either siC, siPGC-1a, or
siERRa. Fold changes are normalized to actin
levels (n = 3).
(G) Immunoblots of MTHFD1L levels in control NT2196 cells (C) and NT2196 cells overexpressing PGC-1a (PGC-1a). Fold changes are normalized to
actin levels (n = 3).
For (F) and (G), data are presented as means + SEM, *p < 0.05, Student’s t test.
See also Figure S3.influences sensitivity to anti-folate therapy. Anti-folates are com-
mon chemotherapeutic drugs used to treat several cancers,
including breast cancer (Munzone et al., 2012). Indeed, cells
that are rapidly dividing and require high levels of nucleotides
are particularly sensitive to these drugs. We used the anti-folate
drug methotrexate (MTX) to study whether the PGC-1a/ERRa
axis influences the sensitivity of breast cancer cells to this
drug. MTX treatment decreased cell numbers significantly
more in murine NT2196 cells overexpressing PGC-1a relative
to controls (Figure 5A). Conversely, reduction of both PGC-1a
and ERRa using siRNA in human BT474 cells led to higher cell
counts after MTX treatment compared with cells transfected
with control siRNA (Figure 5B). This result was paralleled with
lower levels of cleaved caspase 3 in cells depleted of PGC-1a924 Cell Reports 14, 920–931, February 2, 2016 ª2016 The Authorsand ERRa upon MTX treatment (Figure 5C). Furthermore, AICAR
treatment, which induces the expression and activity of PGC-1a/
ERRa and causes a decrease in cell proliferation (Figures 1 and
4D; Figure S4A), potentiated the effect ofMTX on proliferation, as
illustrated by lower cell counts when cells were treated with both
AICAR and MTX compared with either treatment alone (Fig-
ure S4D). Together, these data show that the PGC-1a/ERRa
axis sensitizes cells to anti-folate therapy in vitro.
Next, we wanted to validate the role of PGC-1a/ERRa in
response to anti-folate therapy in vivo. To do so, we performed
xenograft experiments where NT2196 cells overexpressing
PGC-1a were injected on the right flank of the animal, and con-
trol cells were injected on the left flank. Once tumors reached a
volume of 0.1 cm3, MTX treatment was started for 21 days using
Figure 4. The PGC-1a/ERRa Axis Inhibits de Novo Purine Biosynthesis
(A) BrdU incorporation assay for BT474 cells transfected with siC, siPGC-1a, or siERRa. Data are normalized to siC (n = 6) (dashed line). Data are presented as
means + SEM, *p < 0.05, Student’s t test.
(B) BT474 cell counts following siRNA transfection with either siC, siPGC-1a, or siERRa. Data are normalized to siC (n = 6) (dashed line). Data are presented as
means + SEM, *p < 0.05, Student’s t test.
(C) BrdU incorporation assay for BT474 treated with 0.5 mM AICAR or vehicle for 96 hr (n = 7). Data are presented as means + SEM, *p < 0.05, Student’s t test.
(D) BT474 cell counts following treatment with 0.5 mM AICAR or vehicle for 96 hr. Data are normalized to vehicle (n = 6) (dashed line). Data are presented as
means + SEM, *p < 0.05, Student’s t test.
(legend continued on next page)
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a suboptimal dosage that allows for the sustained growth of con-
trol cells during the course of the experiment, as determined in a
pilot study. This experimental design, in which the cells overex-
pressing PGC-1a and controls are injected in the same animal,
also limits the confounding effect of inter-individual variation in
response to MTX treatment that could have arisen if the PGC-
1a and control cells had been injected in different animals (Fig-
ure 5D). As previously reported (Klimcakova et al., 2012), cells
overexpressing PGC-1a generated endpoint tumorsmuch faster
than controls (Figures 5E, compare the red and blue lines, and
5F), even though they displayed reduced expression ofMTHFD1
and GART and had reduced formate levels (Figures 5G and
5H, blue bars), indicating reduced one-carbon metabolism.
Indeed, even though cells overexpressing PGC-1a have reduced
one-carbon metabolism (Figures 3 and 4) and proliferate less
in vitro, they form larger tumors in xenograft experiments, mainly
due to their increased angiogenesis and intratumoral nutrient
levels compared to control cells, as previously described (Klim-
cakova et al., 2012; McGuirk et al., 2013; Figure S5). Clearly, the
elevated nutrient levels in PGC-1a overexpressing tumors over-
come their baseline reduction in one-carbon metabolism. This is
particularly relevant in the context that PGC-1a/ERRa limit one-
carbon metabolism but do not block it completely (Figures 3
and 4) and that these cells are particularly sensitive to nutrient
deprivation (McGuirk et al., 2013).
Importantly, MTX treatment significantly decreased the
growth of PGC-1a overexpressing tumors compared to vehicle
treated mice (Figures 5E, compare the green and blue lines,
and 5F), whereas it had little effect on that of control tumors at
the suboptimal dosage used in the experiment (Figures 5E,
compare the yellow and red lines, and 5F). Indeed, after MTX
treatment, the PGC-1a overexpressing tumors were similar in
size to the controls (Figures 5E and 5F). The fact that cells over-
expressing PGC-1a proliferate less and are more sensitive to(E) Expression of de novo purine biosynthesis genes in BT474 cells transfected
presented as means + SEM, *p < 0.05, Student’s t test.
(F) Standard ChIP-qPCR of ERRa binding to PPAT, GART, and ATIC in BT474 c
(G) Relative expression ofGART,ATIC, and PPAT in BT474 cells transfected with s
that of siC cells treated with vehicle. One representative experiment of two inde
means and SEM, *p < 0.05; **p < 0.01; ***p < 0.001 indicate that siERRa induces a s
(H) Immunoblots of GART and ATIC in BT474 cells transfected siC or siERRa. Fold
SEM, *p < 0.05, Student’s t test.
(I) Expression of de novo purine biosynthesis genes in NT2196 cells overexpressin
means + SEM, *p < 0.05, Student’s t test.
(J) Stable isotope tracer analysis experiment. Labeled serine (13C3-
15N-serine)
metabolites linked to the folate cycle activity was monitored. AMP and ATP come
metabolite from the methionine cycle that is linked to the folate cycle. 5,10-MTH
boxes depict the metabolites that were analyzed in (K)–(N).
(K) Mass isotopomer enrichment of AMP in BT474 cells transfected with either siC
as means + SEM, *p < 0.05, Student’s t test.
(L) Mass isotopomer enrichment of ATP in BT474 cells transfected with either
experiment performed in triplicate of three independent experiments is shown. D
(M) Mass isotopomer enrichment of SAM in BT474 cells transfected with either siC
as means + SEM, *p < 0.05, Student’s t test.
(N) Mass isotopomer enrichment of ATP in control NT2196 cells (C) and NT2196
(n = 3). Data are presented as means + SEM, *p < 0.05, Student’s t test.
(O) Formate levels in control NT2196 cells (C) and NT2196 cells overexpressing
Student’s t test.
See also Figure S4.
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are also more sensitive to MTX in vivo (Figures 5E and 5F) high-
lights that the relative growth status of these cells does not
dictate their MTX sensitivity. Taken together, our results indicate
that the PGC-1a/ERRa axis is a central modulator of the
response of HER2+ mammary tumors to MTX treatment.
DISCUSSION
In this study, we report functional interactions between the en-
ergy sensor AMPK and the PGC-1a/ERRa transcriptional part-
ners in breast cancer cells. PGC-1a/ERRa were shown to be
important for the increased mitochondrial activities of breast
cancer cells after AMPK activation. We also uncovered that
one-carbon metabolism was a key metabolic pathway targeted
by the AMPK/PGC-1a/ERRa axis. Indeed, the expression of
several folate cycle genes was negatively regulated by PGC-
1a/ERRa under basal conditions, and it was further repressed
in a PGC-1a/ERRa-dependent manner upon activation of
AMPK. This transcriptional regulation of folate cycle genes led
to decreased purine biosynthesis and SAM replenishment,
which are key end metabolites of one-carbon metabolism.
Hence, we show that PGC-1a/ERRa are central effectors
of both catabolic (increased mitochondrial respiration) and
anabolic (inhibition of purine biosynthesis) metabolic pathways.
The clinical relevance of our data is illustrated by the fact that
breast cancer cells with elevated levels of PGC-1a/ERRa display
reduced folate metabolism and increased sensitivity to anti-
folate therapy.
Folate intermediates play diverse roles in cellular meta-
bolism. Notably, through their integration into one-carbon meta-
bolism, folates are important for transfer of one-carbon units
for the biosynthesis of nucleotides (Locasale, 2013). Serine do-
nates a one-carbon unit to tetrahydrofolate (THF), generatingwith siC, siPGC-1a, or siERRa. Data are normalized to siC (n = 3–4). Data are
ells treated with 0.5 mM AICAR or vehicle for 90 min (n = 3).
iC or siERRa and treated with 0.5 mMAICAR or vehicle for 24 hr, normalized to
pendent experiments performed in triplicate is shown. Data are presented as
ignificant change comparedwith the respective siC condition (Student’s t test).
changes are normalized to tubulin levels (n = 3). Data are presented asmeans +
g PGC-1a (PGC-1a) normalized to that of controls (n = 3). Data are presented as
was added to cultured cells, and incorporation of labeling into downstream
from the purine synthesis pathway, whereas S-adenosyl methionine (SAM) is a
F: 5,10-methyleneTHF, 5-MTHF: 5-methylTHF, 10-FTHF: 10-formylTHF. Red
or siERRa and pulsed with 13C3-
15N-serine for 8 hr (n = 3). Data are presented
siC or siERRa and pulsed with 13C3-
15N-serine for 8 hr. One representative
ata are presented as means + SEM, *p < 0.05, Student’s t test.
or siERRa and pulsed with 13C3-
15N-serine for 8 hr (n = 3). Data are presented
cells overexpressing PGC-1a (PGC-1a) pulsed with 13C3-
15N-serine for 8 hr
PGC-1a (PGC-1a) (n = 3). Data are presented as means + SEM, *p < 0.05,
Figure 5. The PGC-1a/ERRa Axis Sensitizes
Breast Cancer Cells to MTX Treatment
In Vitro and In Vivo
(A) Cell counts of control NT2196 cells (C) and
NT2196 cells overexpressing PGC-1a (PGC-1a)
treated with 0.1 mM MTX for 96 hr, normalized to
control cells (C) treated with MTX (n = 3). Data are
presented as means + SEM, *p < 0.05, Student’s
t test.
(B) Cell counts for BT474 cells transfected with siC
or both siPGC-1a and siERRa and treated with
100 mM MTX for 72 hr, normalized to cells treated
with vehicle. Data are presented as means + SEM,
***p < 0.001, Student’s t test.
(C) Immunoblots of ERRa, PGC-1a, and cleaved
caspase 3 in BT474 cells treated as described
for (B).
(D) Control or PGC-1a overexpressing NT2196
cells were injected intomammary fat pads of SCID/
BEIGE mice. Control cells were injected in the
left flank, whereas PGC-1a overexpressing cells
were injected in the right flank of each mouse.
Once tumors reached approximately 0.1 cm3
(18–23 days post-injection), mice were treated
with 5.56 mg/kg of MTX or vehicle twice weekly
until the tumors reached approximately 1.5 cm3.
(E) Tumor growth curves. Top panel, control
tumors; bottom panel, PGC-1a overexpressing
tumors.
(F) Tumor masses and images of tumors at
endpoint from each group (n = 5–7). Data are pre-
sented as means ± SEM, **p < 0.01; ***p < 0.001,
Student’s t test.
(G) Expression of MTHFD1 and GART in PGC-1a
overexpressing tumors treated with vehicle or
MTX, normalized to control tumors treated with
vehicle or MTX (n = 5–7). Data are presented as
means + SEM, *p < 0.05, Student’s t test.
(H) Formate levels in PGC-1a overexpressing tu-
mors treated with vehicle or MTX, normalized to
control tumors treated with vehicle or MTX (n = 5).
Data are presented as means + SEM, *p < 0.05,
Student’s t test.
See also Figure S5.5,10-methylene-THF, a folate intermediate that can ultimately
produce purines (Locasale, 2013). A recent study showed that
a significant amount of NADPH in cells is generated through
the conversion of 5,10-methylene-THF to 10-formyl-THF (Fan
et al., 2014), identifying this pathway as a major contributor to
the NADP/NADPH ratio. Given the central role of the folate
pathway and one-carbon metabolism in the generation of key
metabolites sustaining cell growth, it is perhaps not surprising
that when examining for altered metabolic pathways across
numerous cancer types, mitochondrial one-carbon metabolism,
notablyMTHFD2, emerged as themost significant (Nilsson et al.,
2014). Furthermore, several studies have shown that cancer
cells are highly dependent on serine, a key substrate for one-
carbon metabolism, for their growth (Labuschagne et al., 2014;CLocasale and Cantley, 2011a, 2011b; Maddocks et al., 2013;
Tedeschi et al., 2013), and serine deprivation augments the
antineoplastic activity of the metabolic drug metformin (Gravel
et al., 2014). The dominant role of folate and one-carbon meta-
bolism in sustaining cell proliferation is further highlighted by
the fact that numerous cancer drugs target key enzymes in these
pathways and that several biomarkers of one-carbon meta-
bolism exist to detect cancer or predict therapeutic response
(Locasale, 2013).
Despite the central role of folate metabolism in cancer, little is
known regarding the regulation of the expression of folate cycle
enzymes. In this study, we demonstrate that PGC-1a/ERRa con-
trol the expression of numerous folate cycle genes, leading to
changes in purine biosynthesis and modulation of sensitivity toell Reports 14, 920–931, February 2, 2016 ª2016 The Authors 927
anti-folate therapy. One interesting feature of the transcriptional
regulation of folate cycle genes by PGC-1a/ERRa is that they act
as repressors of their expression. Most studies on PGC-1a/
ERRa have revealed that they promote the expression of
numerous enzymes involved in metabolism (Gigue`re, 2008).
Indeed, PGC-1a/ERRa coordinately regulate the expression of
numerous citric acid cycle enzymes and electron transport chain
components resulting in elevated mitochondrial bioenergetics
capacity (Eichner andGigue`re, 2011). Similarly, we have recently
shown that PGC-1a/ERRawork together to increase the expres-
sion of many enzymes involved in glutamine metabolism and
promoting glutamine usage (McGuirk et al., 2013). However,
PGC-1a/ERRa have also been shown to function as repressors
of the expression of specific targets. Indeed, PGC-1a represses
the expression of LDHA in muscle (Summermatter et al., 2013)
and b-secretase/BACE1 in brain (Wang et al., 2013). ERRa
also negatively regulates the expression of PEPCK, one of the
key enzyme in hepatic gluconeogenesis (Herzog et al., 2006).
Our data now highlight that PGC-1a and ERRa can also work
together to repress numerous enzymes in a metabolic pathway
causing suppression of its activity. PGC-1a/ERRa cause small
and coordinated changes in the expression of numerous en-
zymes involved in one-carbon metabolism. This is in agreement
with numerous studies showing that PGC-1a/ERRa lead to small
and coordinated changes in the expression of numerous genes
that are metabolically related (St-Pierre et al., 2006; Mootha
et al., 2003). For example, PGC-1a/ERRa regulate the expres-
sion of OXPHOS, ROS detoxification, and glutamine metabolism
genes by eliciting small changes in their expression. Yet, the
concerted biological impact of these modest changes in gene
expression is profound (Wu et al., 1999; St-Pierre et al., 2006;
McGuirk et al., 2013).
Both PGC-1a and ERRa play important roles in the metabolic
reprogramming of cancer cells. Most studies investigating the
role of the PGC-1a/ERRa transcriptional axis in breast cancer
have associated PGC-1a and ERRa with increased tumor
growth, notably by altering metabolism and promoting angio-
genesis (recently reviewed in Bianco et al., 2012; Deblois and Gi-
gue`re, 2013; Deblois et al., 2013). At first glance, this could seem
to be in apparent contradiction with the results reported here,
where the PGC-1a/ERRa axis promotes tumor growth and re-
presses folate metabolism, which is one of the main metabolic
pathways upregulated in cancer as it promotes nucleotide syn-
thesis for DNA replication in rapidly dividing cells. However,
PGC-1a/ERRa regulate numerous metabolic pathways that indi-
vidually may have a different impact on cancer cell proliferation
and survival. Hence, the net effect of PGC-1a/ERRa on tumor
growth will represent the balance between the activity of all
downstream programs. High levels of PGC-1a/ERRa activity
will confer an advantage to maximize energy production by pro-
moting mitochondrial metabolism and angiogenesis to sustain
the high metabolic needs of rapidly dividing cells, as well as
increasing their stress resistance capacity (Arany et al., 2008;
Klimcakova et al., 2012; St-Pierre et al., 2006). In this context,
repression of folate cycle metabolism by the PGC-1a/ERRa
axis is probably largely compensated for by these other PGC-
1a/ERRa-dependent metabolic programs that fuel tumor growth
and promote survival. In support of this point, cells overexpress-928 Cell Reports 14, 920–931, February 2, 2016 ª2016 The Authorsing PGC-1a proliferate less in vitro, whereas they formed larger
tumors in vivo. Themain reason for their increased growth in vivo
is their elevated levels of intratumoral nutrients (Klimcakova
et al., 2012; Figure S5B), which clearly overcome the baseline
reduction in one-carbon metabolism (Figures 3, 4, and 5). How-
ever, when examining the gain and loss of function experiments
performed in vitro, where nutrient levels are abundant and iden-
tical, PGC-1a/ERRa levels are inversely correlated with one-car-
bonmetabolism and cell proliferation. Indeed, cells overexpress-
ing PGC-1a display a reduction in one-carbon metabolism and a
reduction in proliferation, whereas cells with reduced levels of
PGC-1a/ERRa display an increase in one-carbon metabolism
and an increase in proliferation (Figure 4; Figure S5).
The sensitivity to anti-folate treatment was correlated with
PGC-1a/ERRa expression levels rather than with proliferation
capacities. Indeed, cells overexpressing PGC-1a proliferate
less and are more sensitive to MTX in vitro (Figure 5A), although
they form larger tumors that are also more sensitive to MTX
in vivo (Figures 5E and 5F). Hence, the relative growth capacity
of these cells does not determine their MTX sensitivity. Clearly,
the PGC-1a/ERRa-dependent metabolic programs that confer
a growth advantage to PGC-1a overexpressing tumors can no
longer counterbalance for the inhibition of folate cycle meta-
bolism in the presence of MTX; hence, these tumors lose their
growth advantage (Figure 6).
Overall, our results may have potentially significant clinical im-
plications because they suggest that patients with tumors ex-
pressing high levels of PGC-1a/ERRamay be particularly sensi-
tive to MTX treatment. Importantly, subsets of melanomas
(Vazquez et al., 2013) and prostate tumors (Tennakoon et al.,
2014) with elevated levels of PGC-1a have been defined, and
our data suggest that these cancer patients may benefit from
anti-folate therapy. In that context, it is also tempting to specu-
late that AMPK activators, such as AICAR or metformin, could
be used to sensitize cancer patients to adjuvant treatments tar-
geting the folate pathway.
EXPERIMENTAL PROCEDURES
Cell Lines and Reagents
BT474 and SKBR3 cell lines were purchased from ATCC and cultured as pre-
viously described (Deblois et al., 2009). NT2196-PGC-1a and control NT2196
stable cell lines were cultured and prepared as previously described (Ursini-
Siegel et al., 2007; Klimcakova et al., 2012). AMPK null MEFs were a generous
gift from Dr. Arnim Pause’s laboratory (McGill University; Yan et al., 2014).
AICAR, metformin, and MTX were purchased from Sigma. A769662 was pur-
chased from Abcam.
siRNA Transfection
Cells were transfected immediately upon seeding with either control
siRNA (siC) (Dharmacon), an siRNA pool targeting ESRRA (siERRa) (ON-TAR-
GETplus siRNA pool, Dharmacon), an siRNA pool targeting PPARGC1A
(siPGC-1a) (QIAGEN), or both siPGC-1a and siERRa (siPGC-1a/siERRa) using
HiPerFect reagent (QIAGEN) or calcium phosphate. Cells were transfected for
36 hr, and then they were treated with AICAR, A769662, MTX, or the corre-
sponding vehicle for 24 to 96 hr.
Microarray Analysis
BT474 cells were treated with 0.5 mM AICAR for 1 day or 4 days, and RNA
was extracted and purified using an Aurum Total RNA Mini Kit (Bio-Rad).
RNA was hybridized to GeneChip Human Genome U133 Plus 2.0 (Affymetrix)
Figure 6. The PGC-1a/ERRa Axis Modulates One-Carbon Meta-
bolism and MTX Sensitivity
Schematic representation of the impact of the relative levels of PGC-1a/ERRa
(top panel, low; bottom panel, high) on catabolic and anabolic metabolism in
cancer cells. Our model indicates that cancer cells with higher levels of PGC-
1a/ERRa have a greater sensitivity to MTX and that AMPK activators, such as
AICAR and metformin, could further enhance PGC-1a/ERRa activity and
therapeutic response.and quantified at Ge´nome Que´bec Innovation Centre (McGill University). The
expression data were analyzed using FlexArray10 software. Microarray data
are available in the GEO database (GEO: GSE75877).
qRT-PCR
RNA was extracted and purified using the RNeasy Mini Kit (QIAGEN) or the
Aurum Total RNA Mini Kit (Bio-Rad) following the manufacturers’ protocols.
Reverse transcriptase reactions were performed using SuperScript II (Invitro-
gen) or iScript cDNA Synthesis Kit (Bio-Rad). Samples were then analyzed by
qRT-PCR with SYBR-green-based qRT-PCR with a LightCycler 480 instru-Cment (Roche) or a MyiQ2 Real-Time Detection System (Bio-Rad). Gene-spe-
cific primers are found in Table S1.
ChIP-Seq and ChIP-qPCR
BT474, SKBR3, or MEFs were plated 24 hr in complete media before being
treated with fresh media containing 0.5 mM AICAR or vehicle for 90 min. Cells
were then cross-linked with 1% formaldehyde, and ChIP-qPCR or ChIP-seq
were performed as previously described (Chaveroux et al., 2013) with an
anti-ERRa rabbit antibody (Abcam 2131) or a control anti-rabbit IgG antibody
(Sigma-Aldrich 10500C). Pathway analyses were performed with Ingenuity
Pathways Analysis software (Ingenuity Systems [IPA]) using genes with peaks
foundwithin ± 20 kb of the transcription start site to study significantly enriched
pathways. Gene-specific primers are found in Table S2.
Western Blotting
Protein extracts were prepared using lysis buffer (50 mmol/L Tris-HCl [pH 7.4],
1% Triton X-100, 0.25% sodium deoxycholate, 150 mmol/L NaCl, 1 mmol/L
EDTA) or buffer K (Chaveroux et al., 2013) supplemented with protease
and phosphatase inhibitors. Immunoblots were incubated with the following
primary antibodies from Cell Signaling Technology: pAMPK (2531), AMPK
(2532), pACC (3661), ACC (3662), Caspase 3 (9662); from Santa Cruz:
Actin (sc-1616); fromAbcam:MTHFD1 (ab103698), ERRa (ab2131), MTHFD1L
(ab153840), PGC-1a (ab54481); from Bethyl Laboratories: ATIC (A304-
271A-T) and GART (A304-311A-T); and from Cedarlane: a-tubulin (CLT-
9002). The results were visualized with Western Lightning Plus-ECL
(PerkinElmer) and analyzed with ImageJ software (NIH).
Respiration
Cellular respiration was determined as described previously (Fantin et al.,
2006). BT474 and SKBR3 cells were treated for 96 hr with 0.5 mM and
0.25 mM AICAR, respectively.
Stable Isotope Tracing Experiments and Metabolite Quantification
Intratumoral glucose and glutamine levels, as well as stable isotope tracer
analyses, were determined at the Metabolomics Core Facility of the Goodman
Cancer Research Centre using standard protocols (see the Supplemental
Experimental Procedures).
BrdU Assay
The BrdU assay was conducted using the 5-Bromo-20-deoxy-uridine labeling
and detection kit III (Roche) according to the manufacturer’s instructions.
Xenograft Assays
For in vivo xenograft experiments, 53 104 cells re-suspended in 30 ml of sterile
PBS were injected on each side of the mouse in the mammary gland fat pad of
5- to 7-week-old SCID/BEIGE mice (Taconic). Control or PGC-1a overex-
pressing cells (PGC-1a), derived from NT2196 as previously described (Klim-
cakova et al., 2012), were injected in the left or right mammary fat pad, respec-
tively. Following cell injection, tumor growth was monitored twice a week with
calipers. I.p. injections of MTX (5.56 mg/kg) were given twice a week when tu-
mors on both sides reached a volume of at least 0.1 cm3. Tumor monitoring
was continued twice a week, and animals were sacrificed when the total tumor
volume reached 1.5 cm3. Tumors were excised, weighed, and flash frozen in
liquid nitrogen for subsequent analyses. All animal studies were approved by
the McGill University Animal Care Committee.
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